You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 269 No. 15, April 21, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring

J. B. Redman, R. G. Fenwick Jr, Y. H. Fu, A. Pizzuti and C. T. Caskey
Institute for Molecular Genetics, Baylor College of Medicine, Houston, TX 77030.

OBJECTIVE--To assess the relationship between the GCT repeat number in the myotonic dystrophy gene and the clinical phenotype and examine its predictive utility in prenatal testing. DESIGN--DNA from patients was examined for the length of the myotonic dystrophy GCT repeat region, using both Southern blot analysis and polymerase chain reaction. The results were compared with the clinical onset of disease, as well as with pregnancy outcomes. SETTING--Patient samples were referred to the Kleberg DNA Diagnostic Laboratory at the Baylor College of Medicine for DNA analysis by geneticists and genetic counselors (84%), neurologists (10%), and obstetricians and other specialists (6%). Clinical features including onset of disease and family pedigrees were determined by the referring centers. PATIENTS--A total of 241 patient samples from 118 families referred from primarily genetic or neurological centers for genetic linkage analysis or mutation analysis for myotonic dystrophy. This included 44 families referred for prenatal diagnosis. MAIN OUTCOME MEASURES--A relationship between myotonic dystrophy disease onset and length of the GCT repeat allele, parental origin of the disease allele, and results of prenatal diagnosis predictions of disease status were measured. RESULTS--There is a relationship between increasing repeat length and earlier clinical onset of disease. Essentially all (> 99%) myotonic mutations causing myotonic dystrophy are accounted for by GCT repeat amplification. Congenital myotonic dystrophy occurs with as few as 730 GCT repeats but only with alleles of maternal origin. Maternal GCT repeats were found as low as 75 (asymptomatic) that were amplified to result in a child with congenital myotonic dystrophy. Application of DNA diagnosis to 32 pregnancies provided an accurate method for identification of at-risk fetuses and allele enlargement. CONCLUSIONS--The GCT repeat in myotonic dystrophy is highly mutable. The triplet repeat amplification is highly specific for mutations involving the myotonin protein kinase gene accounting for myotonic dystrophy. The quantitation of triplet repeats can be more sensitive than physical, ophthalmologic, and electromyography examinations since the mutation can be detected in patients without evidence of myotonic dystrophy clinical findings. The length of the triplet expansion is influenced by the sex of the transmitting parent and is related to the clinical onset of disease features. Prenatal measurement of the GCT triplet repeat has utility for families with myotonic dystrophy risk since mutant and normal repeats are distinguishable and the length of mutant repeat alleles is associated with clinical severity. Thus, GCT triplet measurement provides a highly accurate means of detecting the myotonic dystrophy mutation in patients and offers a new reproductive option for families at risk for myotonic dystrophy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Myotonic dystrophy: does it affect ovarian follicular status and responsiveness to controlled ovarian stimulation?
Feyereisen et al.
Hum Reprod 2006;21:175-182.
ABSTRACT | FULL TEXT  

Congenital Myotonic Dystrophy: Assisted Ventilation Duration and Outcome
Campbell et al.
Pediatrics 2004;113:811-816.
ABSTRACT | FULL TEXT  

Proximal Myotonic Myopathy: Clinical, Neuropathologic, and Molecular Genetic Features
Eisenschenk et al.
Annals of Clinical & Laboratory Science 2001;31:140-146.
ABSTRACT | FULL TEXT  

Frequency and stability of the myotonic dystrophy type 1 premutation
Martorell et al.
Neurology 2001;56:328-335.
ABSTRACT | FULL TEXT  

Is it possible to identify infrahissian cardiac conduction abnormalities in myotonic dystrophy by non-invasive methods?
Babuty et al.
Heart 1999;82:634-637.
ABSTRACT | FULL TEXT  

Unstable expansion of the CAG trinucleotide repeat in MAB21L1: report of a second pedigree and effect on protein expression
Margolis et al.
J. Med. Genet. 1999;36:62-64.
ABSTRACT | FULL TEXT  

Disruption of Splicing Regulated by a CUG-Binding Protein in Myotonic Dystrophy
Philips et al.
Science 1998;280:737-741.
ABSTRACT | FULL TEXT  

Proton Spectroscopy in Myotonic Dystrophy: Correlations With CTG Repeats
Chang et al.
Arch Neurol 1998;55:305-311.
ABSTRACT | FULL TEXT  

Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice
Roberts et al.
Proc. Natl. Acad. Sci. USA 1997;94:13221-13226.
ABSTRACT | FULL TEXT  

Myotonic Disorders in Childhood: Diagnosis and Treatment
Moxley
J Child Neurol 1997;12:116-129.
ABSTRACT  

The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation.
Justice et al.
Genes Dev. 1995;9:534-546.
ABSTRACT  

Unstable Triplet Repeat Diseases
Monckton and Caskey
Circulation 1995;91:513-520.
ABSTRACT | FULL TEXT  

Characterization and Functional Implications of the RNA Binding Properties of Nuclear Factor TDP-43, a Novel Splicing Regulator of CFTR Exon 9
Buratti and Baralle
J. Biol. Chem. 2001;276:36337-36343.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.